EnVVeno Medical Corp (NVNO)
enVVeno Medical Corp is a clinical-stage medical device company listed on NASDAQ under the ticker NVNO. The company develops bioprosthetic, tissue-based solutions aimed at improving treatment options for venous disease. Its lead program is VenoValve, a replacement venous valve designed for patients with chronic venous insufficiency and implanted through an open surgical procedure in the femoral vein. enVVeno Medical is also working on enVVe, a non-surgical, transcatheter-based venous valve system that includes the valve, delivery system, and related accessories. Founded in 1999 and based in Irvine, California, the company was previously known as Hancock Jaffe Laboratories, Inc. before adopting its current name in October 2021.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-NVNO
|
$12.43
|
36.6% Upside
|
Undervalued
|
$30
|
229.7% Upside
|
Bargain
|
Fair
|
0.0%
|
November 5, 2026
|
0.3x
|
6.213 M
|
-14.802 M
|
7.6%
|
86.5%
|
-10.9
|
93.0%
|